- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03605212
Febuxostat for Tumor Lysis Syndrome Prevention in Hematological Malignancies of Paediatric Patients and Adults (FLORET)
May 10, 2021 updated by: Menarini Group
Open Label, Multi-centre, Parallel Group Study to Compare the Pharmacokinetics (PK), Pharmacodynamics (PD) and Safety of Febuxostat Between Pediatric Patients (≥6<18 Years of Age) and Adults
The purpose of this study is to compare the exposure of febuxostat in pediatric patients (≥6<18 years of age) and in adults suffering from hematological malignancies at intermediate to high risk of TLS and to compare the effect in terms of serum uric acid levels.
Study Overview
Detailed Description
In the FLORET study it is planned to enroll 3 groups of patients in order to receive oral administration (film-coated tablets) of two different dose levels of febuxostat: children (from 6 to less than 12 years of age) will receive two different dose levels respectively; adolescents (from 12 to less than 18 years of age) will receive 80 and 120 mg/day respectively and adults (equal or major than 18 years of age) will receive 120 mg/day.
The two dose levels for children and adolescents groups were to be sequentially administered, whereas the groups that will receive the first dose levels will simultaneously start the treatment at the study beginning.
The individual treatment duration will be of 7 to 9 days, according to chemotherapy duration, as per Investigator's judgement.
Study Type
Interventional
Enrollment (Actual)
30
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Sofia, Bulgaria, 1527
- University Hospital Tsaritsa Yoanna
-
-
-
-
-
Budapest, Hungary, 1085
- Semmelweis Egyetem
-
Budapest, Hungary, 1083
- Semmelweis Egyetem (paediatric)
-
Debrecen, Hungary, 4032
- Debreceni Egyetem Klinikai Kozpont
-
-
-
-
-
Bologna, Italy, 40138
- Policlinico S. Orsola Malpighi
-
Firenze, Italy, 50139
- Azienda Ospedaliero Universitaria Meyer
-
Firenze, Italy, 50134
- A.O.U.C. Azienda Ospedaliero - Universitaria Careggi
-
Genova, Italy, 16147
- Istituto G Gaslini Ospedale Pediatrico IRCCS
-
Pisa, Italy, 56126
- Azienda Ospedaliero-Universitaria Pisana
-
Rome, Italy, 00165
- IRCCS Ospedale Pediatrico Bambino Gesu
-
Torino, Italy, 10126
- Ospedale Infantile Regina Margherita
-
Verona, Italy, 37126
- Azienda Ospedaliera Universitaria Integrata Di Verona
-
-
Pordenone
-
Aviano, Pordenone, Italy, 33081
- SOC Oncologia Medica A - Centro di Riferimento Oncologico
-
-
-
-
-
Caceres, Spain, 10002
- Hospital de San Pedro de Alcantara
-
Madrid, Spain, 28046
- Hospital Universitario La Paz
-
Madrid, Spain, 28007
- Hospital General Universitario Gregorio Maranon
-
Valencia, Spain, 46026
- Hospital Universitari I Politecnic La Fe
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
6 years and older (Child, Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
male and female children of 6 to less than 12 years of age, adolescents of 12 to less than 18 years of age and adults from 18 years:
- scheduled for first cytotoxic chemotherapy cycle because of hematologic malignancies
- and at intermediate or high risk of TLS
- and with no access to rasburicase
Exclusion Criteria:
- patients with contraindications as per febuxostat summary of product characteristics
- patients with severe renal insufficiency
- patients with severe hepatic insufficiency
- patients with diagnosis of Laboratory TLS (LTLS) or Clinical TLS (CTLS)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cohort 1
Febuxostat film-coated tablets 2x20 mg/QD for 7-9 days
|
Intervention is orally administered to patients in this arm.
|
Experimental: Cohort 2
Febuxostat film-coated tablets 3x20 mg/QD for 7-9 days
|
Intervention is orally administered to patients in this arm.
|
Experimental: Cohort 3
Febuxostat film-coated tablets 1x80 mg/QD for 7-9 days (Adenuric® 80 mg)
|
Intervention is orally administered to patients in this arm.
|
Experimental: Cohort 4
Febuxostat film-coated tablets 1x120 mg/QD for 7-9 days (Adenuric® 120 mg)
|
Intervention is orally administered to patients in this arm.
|
Active Comparator: Adults
Febuxostat film-coated tablets 120 mg/QD for 7-9 days (Adenuric® 120 mg)
|
Intervention is orally administered to patients in this arm.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pharmacokinetic (PK) Parameter: Apparent Clearance (CL/F)
Time Frame: 7 days
|
Apparent clearance of febuxostat from Visit 2 (Day 2) to Evaluation Visit (Visit 8, Day 8)
|
7 days
|
PK Parameter: Apparent Volume of Distribution (Vd/F)
Time Frame: 7 days
|
Apparent volume of distribution of febuxostat from Visit 2 (Day 2) to Evaluation Visit (Visit 8, Day 8)
|
7 days
|
PK Parameter: Absorption Rate Constant (Ka)
Time Frame: 7 days
|
Absorption rate constant of febuxostat from Visit 2 (Day 2) to Evaluation Visit (Visit 8, Day 8)
|
7 days
|
PK Parameter: Area Under Curve (AUC)
Time Frame: 7 days
|
AUC of febuxostat from Visit 2 (Day 2) to Evaluation Visit (Visit 8, Day 8)
|
7 days
|
PK Parameter: Maximum Plasma Concentration (Cmax)
Time Frame: 7 days
|
Maximum plasma concentration of febuxostat from Visit 2 (Day 2) to Evaluation Visit (Visit 8, Day 8)
|
7 days
|
PK Parameter: Tmax
Time Frame: 7 days
|
Time to Cmax from Visit 2 (Day 2) to Evaluation Visit (Visit 8, Day 8)
|
7 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pharmacodynamic (PD) Parameter: Area Under the Curve of Serum Uric Acid (sUA)
Time Frame: 8 days
|
Area under the curve of sUA from baseline (Visit 1, Day 1) to the Evaluation Visit (Visit 8, Day 8) (AUC sUA 1-8)
|
8 days
|
Assessment of Laboratory Tumor Lysis Syndrome (LTLS)
Time Frame: 7 days
|
Assessment of LTLS at Visit 1 (Day 1) and from Start of Chemotherapy (Visit 3, Day 3) to the Evaluation Visit (Visit 8, Day 8).
LTLS is diagnosed if levels of 2 or more values of uric acid, potassium, phosphate or calcium are more than or less than normal at presentation or if they change by at least 25% from baseline.
|
7 days
|
Assessment of Clinical Tumor Lysis Syndrome (CTLS)
Time Frame: 7 days
|
Assessment of CTLS at Visit 1 (Day 1) and from Start of Chemotherapy (Visit 3, Day 3) to the Evaluation Visit (Visit 8, Day 8).
CTLS is present when LTLS is accompanied by at least one of the following significant clinical complications: increased creatinine level ≥ 1.5 upper limit of normal, cardiac arrhythmia/sudden death or seizure.
|
7 days
|
Assessment of Treatment Emergent Signs and Symptoms (TESS)
Time Frame: Estimated maximum time frame: 27 days
|
Assessment of incidence, severity (through Mild/Moderate/Severe scale), seriousness and treatment-causality of TESS from Screening Visit to End of Study Visit.
Adverse events were assessed using Common Terminology Criteria for Adverse Events (CTCAE) version 4.0.
An adverse event was considered as TESS if it occured for the first time or if it worsened in terms of seriousness or severity after first study drug intake.
|
Estimated maximum time frame: 27 days
|
Assessment of Participants Affected by Treatment Emergent Signs and Symptoms (TESS)
Time Frame: Estimated maximum time frame: 27 days
|
Number of participants affected by TESS from Screening Visit to End of Study Visit.
|
Estimated maximum time frame: 27 days
|
Performance Status (PS) Evaluation
Time Frame: Estimated maximum time frame: 27 days
|
Quality of life was to be assessed by PS evaluation from Screening Visit to End of Study Visit.
The Karnofsky Performance Status (KPS) scale was to be used for patients aged 16 years and older; the Lansky Play Performance Status (LPS) scale was to be used for patients aged less than 16 years.
Both scales range from scores of 0 to 100 points at intervals of 10 where 0 points represent the worst outcome (KPS: 0 = death; LPS: 0 = unresponsive) and 100 points the best (KPS: 100 = normal, no complaints, no evidence of disease; LPS: 100 = fully active).
|
Estimated maximum time frame: 27 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Chair: Franco Locatelli, Prof, MD, IRCCS Ospedale Pediatrico Bambino Gesù, Piazza Sant'Onofrio, 4, 00165 Rome, IT
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
February 27, 2017
Primary Completion (Actual)
July 25, 2018
Study Completion (Actual)
July 25, 2018
Study Registration Dates
First Submitted
May 29, 2018
First Submitted That Met QC Criteria
July 19, 2018
First Posted (Actual)
July 30, 2018
Study Record Updates
Last Update Posted (Actual)
June 3, 2021
Last Update Submitted That Met QC Criteria
May 10, 2021
Last Verified
January 1, 2019
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- FLO-02
- 2016-001445-61 (EudraCT Number)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Tumor Lysis Syndrome
-
M.D. Anderson Cancer CenterSanofiCompleted
-
SanofiCompletedCancer | Hyperuricemia | Tumor Lysis SyndromeUnited States
-
SanofiCompletedHyperuricemiaKorea, Republic of
-
M.D. Anderson Cancer CenterSanofiCompletedLymphoma | LeukemiaUnited States
-
M.D. Anderson Cancer CenterSanofiCompletedLymphoma | Leukemia | Tumor Lysis SyndromeUnited States
-
SanofiCompletedHyperuricemia | Tumor Lysis Syndrome | TumorsUnited States
-
M.D. Anderson Cancer CenterActive, not recruitingHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm | Tumor Lysis SyndromeUnited States
Clinical Trials on Febuxostat
-
Bio-innova Co., LtdNot yet recruitingHealthy Subjects
-
Jiangsu HengRui Medicine Co., Ltd.Unknown
-
The Affiliated Hospital of Xuzhou Medical UniversityThe First People's Hospital of XuzhouUnknown
-
University of Mississippi Medical CenterTerminatedBlood Pressure | GoutUnited States
-
Benha UniversityNew Jeddah Clinic HospitalCompletedHemodialysis Complication | Hyperuricemia
-
JW PharmaceuticalRecruitingGoutKorea, Republic of
-
Ningbo No. 1 HospitalNot yet recruitingNonalcoholic Fatty Liver DiseaseChina
-
AstraZenecaCompletedType 2 Diabetes | Albuminuria | HyperuricemiaUnited States
-
Jiangsu HengRui Medicine Co., Ltd.Not yet recruitingPrimary Gout and Hyperuricemia
-
TakedaCompleted